Eli Lilly raises annual profit forecast on sustained weight-loss drug demand

Eli Lilly raised its 2026 adjusted EPS outlook to $35.50-$37.00 from $33.50-$35.00 after posting better-than-expected first-quarter results, supported by steady demand for Zepbound and Mounjaro. The launch of oral GLP-1 Foundayo is an early watchpoint: it was prescribed 3,707 times in the U.S. in the week ended April 17, below expectations of around 8,000, but management says it should broaden GLP-1 access. The stock-focused takeaway is positive on earnings and guidance, partially offset by concerns that rising capex and the slower-than-expected Foundayo rollout could temper upside.

Analysis

The key read-through is not the beat itself but the fact that the market is still underestimating the duration of GLP-1 demand elasticity. Even with slower-than-hoped early uptake for the oral formulation, the company is widening profit guidance, which implies the underlying injectable franchise is still powerful enough to absorb launch friction and pricing pressure. That makes this more of a multi-quarter execution story than a one-quarter sentiment event.

The second-order implication is competitive, not just fundamental: the oral category is likely to be a share-grab against the incumbent rather than a true market expansion in the next 6-12 months. If the launch ramps slower than expected, the near-term loser is likely the competitor’s growth narrative, but the bigger risk is that formulary payers use the slower rollout to push harder on rebates and step-edits across the class, compressing net price assumptions for both players. That dynamic matters because the market tends to capitalize obesity assets on peak penetration assumptions, while reimbursement reality usually arrives later and uglier.

The contrarian setup is that weak initial prescription counts may be less important than investors think if the oral drug is being positioned as an access bridge for the large pool of patients unwilling to start injectables. In that case, the stock can re-rate on the next several data points rather than first-week scripts. The downside catalyst is any sign that launch economics are worse than expected—especially if prescriber conversion remains soft after another 4-8 weeks—because that would force a reset on the oral TAM premium embedded in the shares.

From a factor standpoint, this is likely to support a relative-quality bid in large-cap healthcare while keeping the obesity complex vulnerable to abrupt rotation on payer commentary or competitor launch updates. The market is paying for optionality here; if the company can show even modest acceleration in oral adoption into the summer, the multiple can extend further because investors will begin extrapolating a broader chronic-care funnel rather than a single-product upgrade.

Key Decisions for Investors

• Stay long LLY on any 3-5% post-print pullback; use a 4-8 week horizon and target a re-rating if weekly oral prescriptions accelerate, with downside risk contained by the still-strong injectable base.
• Sell near-dated upside in the obesity basket against LLY strength, specifically short-dated covered calls or call spreads, because the market may be overpricing immediate oral-launch inflection versus a slower 1-2 quarter adoption curve.
• Pair long LLY / short NVO for 1-3 months if payer pressure and launch execution favor the faster commercial platform; risk/reward improves if next prescription prints remain below consensus.
• Avoid chasing broad healthcare beta here; instead rotate into LLY as a relative-quality winner versus small-cap biotech, which remains more exposed to financing and trial-risk resets over the next 30-90 days.
• If oral prescription growth is still subscale after the next monthly update, fade the stock via put spreads rather than outright shorts, since the core franchise can still support earnings and limit downside.